Treatment of peritoneal dialysis related fungal peritonitis with caspofungin plus amphotericin B combination therapy.
Fourtounas
Costas
C
Marangos
Markos
M
Kalliakmani
Pantelitsa
P
Savidaki
Erene
E
Goumenos
Dimitrios S
DS
Vlachojannis
Jannis G
JG
D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use; D002176:Candida albicans / Q000187:drug effects / Q000302:isolation & purification*; D002177:Candidiasis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D000077336:Caspofungin; D004359:Drug Therapy, Combination; D054714:Echinocandins; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000628:therapy; D055666:Lipopeptides; D008297:Male; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects* / Q000379:methods; D010538:Peritonitis / Q000175:diagnosis / Q000188:drug therapy*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D000666:Amphotericin B; D000077336:Caspofungin